TuHURA Biosciences, Inc. Common Stock (HURA)
TuHURA Biosciences, Inc. is a biotechnology company focused on developing innovative therapies in the cancer treatment space. The company emphasizes research and development in immuno-oncology and targeted therapies, aiming to improve outcomes for patients with various cancer types.
Company News
The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.
TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.